Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Blood (2013) 122 (23): 3759–3766.

https://doi.org/10.1182/blood-2013-06-507319

Published: 2013

Includes: Supplemental data

Journal Articles

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Blood (2012) 120 (21): 2720.

https://doi.org/10.1182/blood.V120.21.2720.2720

Published: 2012

Journal Articles

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 787.

https://doi.org/10.1182/blood.V120.21.787.787

Published: 2012

Journal Articles

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Chiara Lobetti-Bodoni, MD, Paola MV Rancoita, PhD, Silvia Montoto, MD, Armando Lopez-Guillermo, MD, Annarita Conconi, MD, Rita Coutinho, MD, Janet Matthews, Silvia Franceschetti, MD, Francesco Bertoni, MD, Franco Cavalli, MD, Michele Ghielmini, MD, Andrew Lister, MD, Emili Montserrat, MD, Emanuele Zucca, MD

Blood (2011) 118 (21): 1593.

https://doi.org/10.1182/blood.V118.21.1593.1593

Published: 2011

Journal Articles

Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome

Blood (2011) 118 (21): 2845.

https://doi.org/10.1182/blood.V118.21.2845.2845

Published: 2011

Journal Articles

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

Annarita Conconi, MD, Silvia Franceschetti, MD, Chiara Lobetti-Bodoni, MD, Anastasios Stathis, MD, Riccardo Bruna, MD, Paola Riccomagno, MD, Francesco Bertoni, MD, Michele Ghielmini, MD, Franco Cavalli, MD, Gianluca Gaidano, Emanuele Zucca, MD

Blood (2011) 118 (21): 2660.

https://doi.org/10.1182/blood.V118.21.2660.2660

Published: 2011

Journal Articles

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Blood (2011) 117 (8): 2405–2413.

https://doi.org/10.1182/blood-2010-07-296244

Published: 2011

Includes: Supplemental data

Journal Articles

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Blood (2010) 116 (21): 992.

https://doi.org/10.1182/blood.V116.21.992.992

Published: 2010

Journal Articles

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

Blood (2010) 116 (21): 3375.

https://doi.org/10.1182/blood.V116.21.3375.3375

Published: 2010

Journal Articles

Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.

Blood (2009) 114 (22): 2808.

https://doi.org/10.1182/blood.V114.22.2808.2808

Published: 2009

Journal Articles

Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.

Blood (2009) 114 (22): 2164.

https://doi.org/10.1182/blood.V114.22.2164.2164

Published: 2009

Journal Articles

Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia.

Blood (2008) 112 (11): 1052.

https://doi.org/10.1182/blood.V112.11.1052.1052

Published: 2008

Journal Articles

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Blood (2008) 112 (11): 3183.

https://doi.org/10.1182/blood.V112.11.3183.3183

Published: 2008

Journal Articles

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Alberto Rocci, MD, Marco Ruella, MD, Irene Ricca, MD, Cristiana Carniti, PhD, Manuela Zanni, MD, Chiara Lobetti Bodoni, MD, Marco Ladetto, MD, Daniele Caracciolo, MD, Mario Boccadoro, MD, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 3025.

https://doi.org/10.1182/blood.V110.11.3025.3025

Published: 2007

Journal Articles

Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.

Marco Ladetto, Daniela Drandi, Loredana Santo, Barbara Mantoan, Michela Boi, Maria Dell’Aquila, Luigia Monitillo, Chiara Lobetti Bodoni, Antonio Palumbo, MD, Monica Astolfi, Mario Boccadoro

Blood (2006) 108 (11): 3413.

https://doi.org/10.1182/blood.V108.11.3413.3413

Published: 2006

Journal Articles

Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.

Irene Ricca, MD, Alberto Rocci, MD, Daniela Drandi, PhD, Mara Compagno, PhD, Roberto Francese, PhD, Paola Omedè, PhD, Loredana Santo, MD, Michela Rosace, PhD, Federica De Marco, MD, Monica Astolfi, PhD, Chiara Lobetti Bodoni, MD, Maria Dell’Aquila, PhD, Sonia Vallet, MD, Luciana Bergui, MD, Andrea Gallamini, MD, Carlo Marinone, MD, Mario Boccadoro, MD, Corrado Tarella, MD, Marco Ladetto, MD

Blood (2005) 106 (11): 2104.

https://doi.org/10.1182/blood.V106.11.2104.2104

Published: 2005

NARROW

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.

Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.

Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia.

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.

Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only